Survival and relapse
cancer, CFS
CANCER, TUMOR PROGRESSION, RECURRENCE, DISTANT METASTASIS
The median follow-up period was 33.3 months (range, 16.2–65.8 months). A total of 27 patients achieved CR. At the time of analysis, local recurrence was observed in five patients, and four of the five patients who could not achieve CR experienced residual primary tumor progression. Pelvic lymph node recurrence was also observed in one patient. Distant metastasis was observed in three patients (in the liver in two patients and in the para-aortic lymph node in one). Consequently, three of the 29 survivors were alive with cancer and two died because of SCCAC at the time of analysis. The 2-year DFS, OS and LC rates were 77.4% (95% CI, 58.4–88.5%), 93.5% (95% CI, 76.6–98.3%) and 83.9% (95% CI, 65.5–92.9%), respectively (Disease-free survival (DFS) (A), overall survival (OS) (B), local control (LC) (C) and colostomy-free survival (CFS) (D).